本页整理公开书目信息，不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成，未完成全文核验，可能有误；具体假设、证明与结论请核对原文。摘要保留来源文本，未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要；缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录，不合计多个记录；关联记录可能包含正式发表版本，不等于此版本单独引用。缺失不视为零，引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配，同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列，再参考通用方法与发表日期。
AI 根据所提供的论文材料归类：摘要围绕机器学习异质性处理效应的置信区间，结合随机化推断、交叉拟合与设计型方法，直接属于因果推断。
异质性处理效应机器学习推断评论：随机化推断方法AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We examine the split‐sample robust inference (SSRI) methodology introduced by Chernozhukov, Demirer, Duflo, and Fernandez‐Val for quantifying uncertainty in heterogeneous treatment effect estimates produced by machine learning (ML) models. Although SSRI properly accounts for the additional variability due to sample splitting, its computational cost becomes prohibitive with complex ML models. We propose an alternative approach based on randomization inference (RI) that preserves the broad applicability of SSRI while eliminating the need for repeated sample splitting. Leveraging cross‐fitting and design‐based inference, the RI procedure yields valid confidence intervals with substantially reduced computational burden. Simulation studies demonstrate that the RI method preserves the statistical efficiency of SSRI while scaling to much larger applications and more complex settings.